Register for our free email digests:
Pharming Group NV
Latest From Pharming Group NV
Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.
APPOINTMENT ROUND UP: GlaxoSmithKline, Sanofi, Immune Design, Clinigen, Advaxis, Nanobiotix and Kite Pharma
This week's round up includes CEO appointments by GSK, who has appointed Brian McNamara CEO of the company's consumer unit, Clinigen and The Grünenthal Group; and executive appointments by Sanofi, where Alan Main has joined as executive vice president consumer healthcare global business unit, Immune Design, Advaxis, Kite Pharma and Bavarian Nordic.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.
Pharming Group, developer of hereditary angioedema therapy Ruconest (conestat alfa), has nominated Mr Robin Wright chief financial officer (CFO) and a member of its management board.
- Large Molecule
- Synthesis Technologies, Production Processes
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Renal System
- Western Europe
- Parent & Subsidiaries
- Pharming Group NV
- Senior Management
Sijmen de Vries, MD, CEO
Robin Wright, CFO
- Contact Info
Pharming Group NV
Phone: (31) 71 5247 400
P.O. Box 451 CR Leiden, 2333
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.